



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

SGC-CBP30

Cat. No.:	HY-15826
CAS No.:	1613695-14-9
Molecular Formula:	C ₂₈ H ₃₃ ClN ₄ O ₃
Molecular Weight:	509.04
Target:	Epigenetic Reader Domain; Histone Acetyltransferase
Pathway:	Epigenetics
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 66.67 mg/mL (130.97 mM; ultrasonic and warming and heat to 60°C)				
	Preparing Stock Solutions	Solvent Concentration Mass	1 mg	5 mg	10 mg
		1 mM	1.9645 mL	9.8224 mL	19.6448 mL
		5 mM	0.3929 mL	1.9645 mL	3.9290 mL
		10 mM	0.1964 mL	0.9822 mL	1.9645 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.91 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.91 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	SGC-CBP30 is a potent and highly selective CBP/p300 bromodomain (K _d s of 21 nM and 32 nM for CBP and p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects ^{[1][2][3]} .
IC ₅₀ & Target	CBP/p300
In Vitro	In ankylosing spondylitis and psoriatic arthritis condition, SGC-CBP30 inhibits IL-17A secretion by Th17 cells. Transcriptional profiling of human T cells after SGC-CBP30 treatment shows a much more restricted effect on gene expression than that observed with the pan-BET (bromo and extraterminal domain protein family) bromodomain inhibitor JQ1 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SGC-CBP30 treatment slightly alleviates alveolar bronchial fibrosis induced by NSC-125066. SGC-CBP30 plus CQ-061 dramatically reduces alveolar bronchial fibrosis. The ELISA of cytokines IL-4 and IFN- γ in BALF demonstrates that combination of SGC-CBP300 and CQ-061 suppresses the activation of IL-4 as well as IFN- γ in NSC-125066 induced IPF murine models to nearly normal levels^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley (SD) rats (aged 3-4 weeks) injected with NSC-125066 ^[2]
Dosage:	25 mg/kg
Administration:	Oral administration; daily; for 14 days
Result:	Slightly alleviated alveolar bronchial fibrosis induced by NSC-125066.

CUSTOMER VALIDATION

- Cell Discov. 2023 Jul 25;9(1):77.
- Immunity. 2024 Feb 13;57(2):364-378.e9.
- Nat Commun. 2021 Sep 20;12(1):5548.
- Blood Cancer J. 2019 Feb 11;9(2):19.
- Acta Pharmacol Sin. 2021 Apr 13.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Hammitzsch A, et al. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10768-73.
- [2]. Tao J, Inhibition of EP300 and DDR1 synergistically alleviates pulmonary fibrosis in vitro and in vivo. Biomed Pharmacother. 2018 Oct;106:1727-1733.
- [3]. Hay DA, et al. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J Am Chem Soc. 2014 Jul 2;136(26):9308-19.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA